30-Second Takeaway
- Psychological interventions for schizophrenia with comorbid SUD show minimal benefit on substance use or overall symptoms.
- Psychedelic-assisted psychotherapy shows real-world antidepressant and anxiolytic effects with acceptable short-term tolerability.
- Emerging neuromodulation and digital personalization strategies improve depression but often perform similarly to less complex comparators.
Week ending February 7, 2026
Frontiers and limits in psychiatric interventions: psychedelics, neuromodulation, SUD comorbidity, digital care, genetics, and AI
Psychological interventions offer little benefit for schizophrenia with co-occurring substance use disorders
This meta-analysis pooled 35 RCTs including 4136 adults with schizophrenia and comorbid substance use disorders across alcohol, cannabis, nicotine, and stimulants. Psychological and psychosocial interventions produced only a very small improvement in overall symptoms versus control (SMD −0.11; 95% CI −0.27 to 0.05; low confidence). There was no meaningful effect on overall substance use reduction (SMD −0.01; 95% CI −0.21 to 0.18; moderate confidence). Separate analyses for alcohol, cannabis, amphetamines, and other stimulants all showed similarly null effects, with apparent benefit mainly in nicotine-focused trials.
Large anxiety GWAS implicates 58 loci and GABAergic signaling
This genome-wide association meta-analysis included 122,341 European-ancestry anxiety cases and 729,881 controls, identifying 58 independent risk variants and 66 biologically supported genes. Fifty-one of the 58 loci replicated in an independent cohort of over one million self-reported anxiety cases and nearly two million controls. Anxiety showed substantial genetic correlation with depression, neuroticism, and other internalizing phenotypes, reinforcing shared vulnerability architecture. Enrichment analyses implicated GABAergic signaling and broad brain-region involvement as key biological pathways.
Psychedelic medicine links acute desynchronization to subacute neuroplasticity and therapeutic response
This review synthesizes cellular, systems, and clinical data on classic psychedelics acting primarily via 5-HT2A receptors. Across models, psychedelics induce acute neural desynchronization that destabilizes entrenched network patterns, followed by a subacute window of enhanced neuroplasticity. Clinical studies across several neuropsychiatric indications suggest psychotherapy delivered in this plasticity window can produce durable symptom improvements. The authors highlight tension between preclinical evidence for non-hallucinogenic analogs and trials linking subjective experience intensity to response.
FAAH inhibition fails to augment exposure therapy or alter circuitry in PTSD
In this randomized trial of 100 adults with PTSD receiving exposure-based psychotherapy, a FAAH inhibitor was compared with placebo as adjunctive treatment. Four weeks of FAAH inhibition significantly increased anandamide but did not enhance clinical response versus placebo. Functional MRI in 76 participants showed no group differences in resting-state connectivity or emotional task-related activation between FAAH and placebo arms. Across participants, greater symptom improvement related to lower vmPFC–right dlPFC connectivity and lower right dlPFC activation, independent of treatment assignment.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.